Revenue segments as reported by the company.

Water

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IDEXX Laboratories

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IDEXX Labs reports robust Q4 performance, eyes international growth

IDEXX Laboratories delivered strong Q4 results with revenue and profit growth, driven by gains in key segments and customer retention.
While facing challenges from inflationary costs and international headwinds, the company aims for continued growth and market differentiation.
Opportunities lie in expanding organic revenue, focusing on international markets, and enhancing customer engagement for future success.

IDEXX reports robust Q1 performance, eyes pet oncology growth

IDEXX Laboratories delivered a strong Q1 performance with revenue and profit growth across segments.
The company's focus on innovation, cloud adoption, and pet oncology diagnostics positions it well for future growth.
Challenges include U.S. clinical vet visit trends and potential market share competition in lab modalities.
Opportunities lie in pet oncology diagnostics, cloud adoption, and international market growth for IDEXX.

IDEXX Laboratories excels in Q2, eyes pet healthcare trends

IDEXX Laboratories demonstrated robust growth in revenues and profitability, driven by strong performance in key segments.
While facing challenges in international markets and margin pressures, the company is poised to capitalize on pet healthcare trends.
Strategic initiatives like product launches and pricing adjustments position IDEXX well for sustained growth and market leadership.

IDEXX Laboratories excels in Q3 earnings amidst capacity challenges

IDEXX Laboratories demonstrated strong financial performance in Q3, driven by revenue growth and operational efficiency.
While facing challenges in clinical visit trends and capacity management, the company's strategic focus on innovation and market expansion positions it well for future growth.
Opportunities lie in addressing capacity constraints, expanding the sales force, and enhancing customer engagement through diagnostics testing.
Overall, IDEXX's commitment to providing integrated solutions and quality services underscores its resilience and potential for sustained success.

IDEXX Labs posts robust Q4 results, eyes growth through innovation

IDEXX Laboratories delivered strong financial performance in Q4 2023 and aims for continued growth in 2024.
The company's focus on innovation, customer feedback, and operational efficiency positions it well for future success.
Challenges include managing expenses, revenue diversification, and maintaining customer value perception.
Opportunities lie in organic revenue growth, margin improvement, and the launch of new diagnostic tests and platforms.

IDEXX Laboratories reports strong Q1 earnings and growth opportunities

IDEXX Laboratories delivered strong financial performance in Q1 2024, driven by solid organic revenue growth and profit gains.
The company remains committed to innovation, customer-centric solutions, and increasing standard of care in Companion Animal Healthcare.
Challenges in clinical visit growth levels and macro impacts on consumer demand are being addressed through operational focus and technology investments.
Opportunities for growth and improvement in software integration and diagnostic utilization dynamics present avenues for future success.

IDEXX Laboratories reports solid Q2 growth amidst sector challenges

IDEXX Laboratories navigated Q2 2024 with solid revenue growth and a focus on innovation and cost management. Despite challenges from sector trends and macroeconomic headwinds, the company remains optimistic about long-term growth prospects. Ongoing launches and a strong balance sheet position IDEXX well for future opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.

IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform

Fecal Dx antigen testing will soon detect the most common intestinal parasites earlier, uncovering more infections WESTBROOK, Maine , Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx® antigen testing platform with the addition of Cystoisospora, a common intestinal parasite that causes diarrhea, weight loss, and dehydration, primarily in young dogs and cats. IDEXX's Fecal Dx antigen testing offers earlier and highly accurate detection of the most common and clinically relevant intestinal parasites of dogs and cats: hookworms, roundworms, whipworms, flea tapeworms, and soon Cystoisospora.

IDEXX Expands Fecal Dx® Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years

AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology cases The global launch of the IDEXX inVue Dx analyzer will begin in late 2024 WESTBROOK, Maine , Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the IDEXX inVue Dx™ Cellular Analyzer, a first-of-its-kind slide-free cellular analyzer to detect the most common cytologic changes found in ear and blood samples. With deep AI learning models trained by IDEXX board-certified pathologists, the in-clinic analyzer provides practitioners with reference-laboratory quality results in 10 minutes.

IDEXX Announces Revolutionary Slide-Free Cellular Analyzer, IDEXX inVue Dx™ Transforming In-Clinic Workflows

Colgate-Palmolive

The pet care industry went through a massive growth spurt during the pandemic when it seemed everyone had to own a companion pet. This lit a fire under pet care stocks.

3 Purrfect Stocks to Buy for the Booming Pet Care Industry

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming institutional investor events: Thursday, January 4, 2024, 1:30 pm EST - Jay Mazelsky, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference in New York, New York. Monday, January 15, 2024, 1:00 pm EST - Jay Mazelsky and members of the IDEXX management team will.

IDEXX Laboratories Schedules Two Institutional Investor Events

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

Idexx (IDXX) Up 11.1% Since Last Earnings Report: Can It Continue?

Alcon Inc. - Registered Shares

Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Idexx Laboratories (IDXX). But which of these two stocks presents investors with the better value opportunity right now?

ALC or IDXX: Which Is the Better Value Stock Right Now?

IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.

IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis

The rapid diagnostic test provides a comprehensive solution for detecting canine leishmaniosis that impacts one in 10 dogs in endemic regions WESTBROOK, Maine , Nov. 8, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the upcoming launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases, including canine leishmaniosis. The SNAP Leish 4Dx Test uses the trusted SNAP 4Dx Plus testing platform, which detects Lyme disease, heartworm disease, ehrlichiosis, and anaplasmosis.

IDEXX Expands SNAP Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-borne Diseases

IDEXX Laboratories operates in the veterinarian health sector and has experienced double-digit revenue growth in recent years. The company is facing short-term headwinds due to lower vet visits caused by economic challenges. IDEXX is focused on clinic efficiency, innovation, and expanding its commercial footprint to drive long-term growth, paving the way for elevated long-term gains.

IDEXX: A Realistic Path To 12-14% Annual Returns

Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Idexx (IDXX) Q3 Earnings: A Look at Key Metrics

Call Start: 8:30 January 1, 0000 9:27 AM ET IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Jay Mazelsky - President and Chief Executive Officer Brian McKeon - Chief Financial Officer John Ravis - Vice President, Investor Relations Conference Call Participants Michael Ryskin - Bank of America Nathan Rich - Goldman Sachs Erin Wright - Morgan Stanley Chris Schott - JP Morgan John Block - Stifel Brandon Vasquez - William Blair Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2023 Earnings Conference Call. As a reminder, today's conference is being recorded.

IDEXX Laboratories, Inc. (IDXX) Q3 2023 Earnings Call Transcript

IDEXX (IDXX) delivers better-than-expected earnings in the third quarter of 2023.

IDEXX (IDXX) Q3 Earnings Top Estimates, '23 Sales View Down

Animal health diagnostic services provider IDEXX Laboratories cut its annual sales forecast, after missing third-quarter revenue estimates on Wednesday, hurt by a slower-than-expected rise in pet owners' visits to vet clinics.

IDEXX cuts annual sales forecast as pet owners remain cautious on vet visits

VeriSign

Apple

Automatic Data Processing

AutoZone

Domino's Pizza

Fortinet

Home Depot

KLA-Tencor

Lam Research

Mastercard

Moderna

Mettler-Toledo

O'Reilly Automotive

Philip Morris

QUALCOMM

Texas Instruments

Waters

YUM! Brands

There is no easy way to select individual stocks. Measures of financial quality can highlight companies that are worth a closer look, but a decision to commit money must also take into consideration both recent developments and a look ahead.

Among the S&P 500, these 20 companies have made the best use of investors' money

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.

IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?

Integra LifeSciences Holdings

Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and Idexx Laboratories (IDXX). But which of these two stocks offers value investors a better bang for their buck right now?

IART vs. IDXX: Which Stock Is the Better Value Option?

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 third quarter results for Wednesday, November 1, 2023 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2023 Earnings Snapshot through a link on the IDEXX website, www.

IDEXX Laboratories to Release 2023 Third Quarter Financial Results

ASML Hld

California Water Service Group

Many investors are used to looking for sectors to make bets on. Technology.

3 Stocks Ready to Rocket on These Global Mega Trends

Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.

Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now

Kimberly-Clark

Given its better prospects, we believe that IDEXX Laboratories stock (NASDAQ: IDXX) is a better pick over Kimberly-Clark stock (NYSE: KMB).

Which Is A Better Pick – Kimberly-Clark Stock Or IDEXX Laboratories?

I recommend a buy rating for IDXX due to the company's attractive long-term growth prospects. They anticipate a recovery in growth and margin expansion. IDXX is noted for its strong fundamentals, including consistent revenue growth and expanding EBITDA margins. A forward P/E multiple of 43x is justified based on historical performance and market comparisons.

IDEXX Laboratories: Long-Term Growth Remains Attractive

Humana

Vertex Pharmaceuticals

Humana delivered better-than-expected second-quarter earnings. Vertex Pharmaceuticals has three potential blockbuster therapies on the way.

3 Top Healthcare Stocks to Buy for August

Fintel reports that on August 2, 2023, Atlantic Equities downgraded their outlook for Idexx Laboratories (NASDAQ:IDXX) from Overweight to Neutral.

News for IDEXX Laboratories Stock (IDXX)